[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 8 sources · 25 days · First seen · Last updated

Genmab clinical trial developments

Overview

Genmab A/S has reported positive clinical trial results for multiple investigational treatments. Initial reports highlighted Phase 1/2 data for the antibody-drug conjugate rinatabart sesutecan (Rina-S) in treating platinum-resistant ovarian cancer. The RAINFOL-01 trial showed a confirmed objective response rate of 45.9% and a median progression-free survival of 9.5 months.

Subsequent developments included successful Phase 3 results for the bispecific antibody petosemtamab in the LiGeR-HN1 trial. When combined with pembrolizumab, petosemtamab met primary endpoints for first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma, reducing the risk of death by 50% compared to pembrolizumab alone. An interim analysis of the LiGeR-HN1 trial reported an odds ratio of 3.17 for objective response, with results remaining consistent regardless of HPV status. Genmab stated the safety profile was well tolerated with no new safety signals observed.

Further clinical successes include data from the Rina-S trial for platinum-resistant ovarian cancer, which showed a 57% reduction in the risk of death. These developments, alongside petosemtamab results in metastatic colorectal cancer, have contributed to significant increases in Genmab shares. The company plans to engage with global regulatory authorities regarding these findings.

Entities

Genmab A/S · petosemtamab · Nasdaq · Everett E. Vokes · Pembrolizumab

Claims

What the coverage asserts, and how many sources carry each claim.

Timeline

  1. [HEALTH] 8 sources
    Genmab petosemtamab combination reduces head and neck cancer death risk by 50%

    Genmab’s Phase 3 LiGeR-HN1 trial shows that combining petosemtamab with Keytruda reduces the risk of death by 50% in patients with certain head and neck cancers.

  2. [HEALTH] 4 sources
    Genmab reports positive Phase 1/2 data for Rina-S in ovarian cancer

    Genmab A/S reported a 45.9% response rate for its Rina-S drug in a Phase 1/2 trial for platinum-resistant ovarian cancer, showing activity across various folate receptor alpha expression levels.

Sources

cancernetwork.com · european-biotechnology.com · ibtimes.com.au · it-boltwise.de · kapitalmarktexperten.de · nordiclifescience.org · thebionews.net · tokenpost.kr

This summary has been updated 1 time: see revision history